Construction and Preliminary Application of COM-B Based Sedentary Behavioural Booster Intervention Programme for Elderly Stroke Patients
Launched by LIU SHUXIAN · Jun 1, 2024
Trial Information
Current as of February 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The goal of this clinical trial is to text about in the application effect of the sedentary behaviour intervention program for elderly stroke patients based on the COM-B model. The main question it aims to answer are:
* Changes in sedentary behaviour in elderly stroke patients Participants will received a 12-week sedentary behaviour intervention programme.
Researchers will compare differences in sedentary behaviour between routine care control and intervention groups.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meet the diagnostic criteria for cerebral infarction and cerebral hemorrhage in the Diagnostic Points for Various Major Cerebrovascular Diseases in China 2019 issued by the Cerebrovascular Disease Group of the Neurology Branch of the Chinese Medical Association;
- • Age ≥60 years;
- • National Institute of Health stroke scale (NIHSS) score \<5 (i.e., mild stroke), stable vital signs, and able to cooperate with the survey;
- • Total sedentary time ≥6 hours/day measured using the International Physical Activity Questionnaire;
- • Resident for ≥6 months in the community residents;
- • Patients or under the guidance of others can use WeChat.
- Exclusion Criteria:
- • Functional ambulation category scale (FAC) score \<2;
- • serious myocardial infarction, cerebral hemorrhage and pulmonary embolism in the acute stage of the need to limit the activities of the situation;
- • is participating in other physical activity or sedentary behavioral intervention programs;
- • severe muscle weakness, fractures and other diseases resulting in limited physical activity;
- • serious mental disorders such as schizophrenia or dementia resulting in severe cognitive impairment;
- • speech and communication disorders.
About Liu Shuxian
Liu Shuxian is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on improving patient outcomes, Liu Shuxian collaborates with leading healthcare professionals and research institutions to design and implement rigorous clinical studies. The organization emphasizes ethical conduct, regulatory compliance, and patient safety, ensuring that all trials are conducted to the highest standards. Through its initiatives, Liu Shuxian aims to contribute significantly to the development of new therapies and treatment modalities that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0